Asia Pacific Infectious Disease Treatment Market

Wockhardt’s Zaynich (cefepime-zidebactam), an antibiotic for complicated urinary tract infections caused by resistant bacteria, won US Food and Drug Administration (FDA) approval on 29 May 2026 and Indian manufacturing and marketing approval from the Central Drugs Standard Control Organisation (CDSCO) on 25 August 2026, the company’s second-quarter FY27 release of 2 November 2026 states, making it the first antibiotic discovered and developed in India to clear the FDA. It lands in the region where resistance is worst: 1 in 3 reported bacterial infections in the World Health Organization (WHO) South-East Asia Region resisted antibiotics, against 1 in 6 worldwide, the WHO surveillance report of 13 October 2025 found. The Asia Pacific infectious disease treatment market covers prescription anti-infective medicines used across Asia Pacific: antibacterials, hepatitis and other antivirals including COVID-19 and influenza drugs, HIV antiretrovirals, antifungals, antimycobacterials and antiparasitics, valued at net manufacturer selling prices. Douglas Insights sizes it at USD 28.8 billion in 2025, from about 1.78 billion treatment courses at an average USD 16.2 each, and at USD 44.8 billion in 2035, a revenue CAGR (compound annual growth rate) of 4.52%. The study is the Asia Pacific row of our worldwide Infectious Disease Treatment Market report, sits beside our U.S. Infectious Disease Treatment Market and Asia Pacific Healthcare Contract Research Organization Market studies inside our healthcare coverage, and every figure follows the Douglas Insights research methodology.

Which drug classes earn the most: antibacterials, antivirals or HIV medicines?

Antibacterials earn the most, 44.0% of 2025 Asia Pacific value, USD 12.7 billion, a Douglas Insights estimate. Antifungals grow fastest, 5.60% a year, from USD 3.17 billion to USD 5.47 billion by 2035.

Antibacterials lead at USD 12.7 billion, well above their 38.6% share in our worldwide model, because hospitals in China, India and Southeast Asia still treat most serious infections with injectable cephalosporins, carbapenems and beta-lactamase inhibitor combinations, and because resistance pushes doctors to costlier second-line drugs sooner. They grow 4.30% a year to USD 19.3 billion. Most courses are cheap generics made in China and India, so value growth comes from the small share of reserve antibiotics used against carbapenem-resistant bacteria, a Douglas Insights estimate.

Hepatitis and other antivirals, USD 6.05 billion or 21.0%, are larger than in other regions because chronic hepatitis B is common in China and Southeast Asia and because Japan buys influenza and COVID-19 antivirals in large volumes each winter; they grow 4.40% a year to USD 9.31 billion. HIV antiretrovirals hold only 14.0%, USD 4.03 billion, against 27.9% worldwide, because most of the region’s 7.1 million people living with HIV take low-priced generic tablets. Antifungals, USD 3.17 billion, grow fastest at 5.60% as more patients in China, Japan and Korea receive cancer treatment and transplants. Antimycobacterials hold USD 1.73 billion, driven by tuberculosis in India, Indonesia, the Philippines and Pakistan, and antiparasitics and antimalarials USD 1.15 billion. Class values for 2035 sum to USD 45.0 billion, 0.29% above the USD 44.8 billion headline, inside our 2.5% tolerance.

Spend by care setting and channel

By care setting, hospital-treated infections carry about 58% of 2025 value, USD 16.7 billion, because public hospitals in China, Japan and Korea dispense most intravenous antibiotics and antifungals, and community infections about 42%, USD 12.1 billion, Douglas Insights estimates. By channel, hospital pharmacies carry about 61%, retail pharmacies 33% and donor and public tenders, mostly HIV, tuberculosis and malaria programmes, about 6%.

What drives anti-infective spend in the region up 4.52% a year?

Asia Pacific anti-infective spend grows 4.52% a year because treatment courses add 3.20% and price per course adds 1.28%, lifting the average course from USD 16.2 in 2025 to about USD 18.4 in 2035, Douglas Insights estimates.

Three forces lift spend, all Douglas Insights estimates unless a source is linked: drug resistance, which moves hospitals to dearer reserve antibiotics and antifungals, adds about 1.70 points; wider access to care in India, Indonesia, Vietnam and the Philippines adds about 2.10 points; and HIV and hepatitis treatment coverage adds about 0.72 points. These sum to the 4.52% rate. Each is set out below.

Resistance and reserve antibiotics: 1.70 points

Resistance adds 1.70 points. One in three reported infections in the WHO South-East Asia Region resisted treatment, double the 1 in 6 global rate, and resistance rose in over 40% of the pathogen-antibiotic pairs monitored, with an average yearly increase of 5% to 15% between 2018 and 2023, the WHO report of 13 October 2025 states; more than 55% of Klebsiella pneumoniae worldwide already resist third-generation cephalosporins. Each switch from a generic cephalosporin course costing a few dollars to a reserve antibiotic course costing hundreds of dollars raises value per course far more than it raises course numbers. Wockhardt booked pre-launch expenses for Zaynich in the quarter to September 2026: earnings before interest, tax, depreciation and amortisation (EBITDA) were Rs 165 crore, or Rs 201 crore excluding those expenses, on revenue of Rs 969 crore, its release of 2 November 2026 shows. Shionogi’s cefiderocol, sold as Fetroja and Fetcroja, moved from a December 2024 filing to approval in Australia in September 2026, its second-quarter FY2026 supplement of 29 October 2026 shows. We expect reserve and new-agent antibiotics to rise from about 12% of antibacterial value in 2025 to about 18% in 2035.

Wider access to treatment: 2.10 points

Access adds the largest share, 2.10 points, through course numbers. More people in India, Indonesia, Vietnam and the Philippines now reach a doctor and a pharmacy, and public insurance schemes pay for hospital antibiotics that families once went without, a Douglas Insights estimate. Tuberculosis shows the gap that remains: an estimated 10.7 million people fell ill in 2024, 8.3 million or about 78% were diagnosed and treated, and India held 25% of cases, Indonesia 10%, the Philippines 6.8%, China 6.5%, Pakistan 6.3% and Bangladesh 3.6%, the WHO Global Tuberculosis Report release of 12 November 2025 states. Those six Asia Pacific countries carry 58.2% of the world’s cases, so each extra diagnosed patient adds a six-month or longer course of antimycobacterials. Courses rise from 1.78 billion in 2025 to about 2.44 billion in 2035.

HIV and hepatitis treatment coverage: 0.72 points

The last 0.72 points come from chronic viral infections. Asia and the Pacific had 7.1 million people living with HIV in 2025, 280,000 new infections and 72% of people living with HIV on antiretroviral therapy, against 78% worldwide, the UNAIDS fact sheet of July 2026 shows. Closing that gap adds patients, but mostly on low-priced generics. Gilead’s liver disease sales, led by hepatitis B and C medicines, rose 13% to USD 927 million in the third quarter of 2026, its results of 29 October 2026 show, a sign that hepatitis treatment still grows where diagnosis improves. Together, (1.0320 x 1.0128) minus 1 gives the 4.52% revenue rate.

What holds back growth: fading COVID-19 and influenza antivirals, reimbursement price cuts or cheap generics?

Three restraints slow Asia Pacific anti-infective spend: falling COVID-19 and influenza antiviral sales, price cuts set by national reimbursement lists and tenders, and generic competition that keeps most courses at a few dollars, Douglas Insights estimates.

Respiratory antivirals are the most visible drag. Shionogi’s acute respiratory virus infection treatments, Xocova (ensitrelvir), Xofluza and Rapiacta, earned JPY 4.9 billion in the six months to September 2026, down 44.0% from JPY 8.7 billion, against a full-year forecast of JPY 30.2 billion that depends on the winter season, its supplement of 29 October 2026 shows. Gilead’s COVID-19 antiviral Veklury fell 69% to USD 86 million in the third quarter of 2026, its third-quarter release states. We take about 0.30 points a year off the antivirals class until 2028.

Reimbursement listing cuts prices in return for volume. China’s National Healthcare Security Administration added 114 medicines to the national reimbursement drug list for 2025, effective 1 January 2026, taking it to 3,253 drugs, and created a separate commercial insurance list of 19 high-value treatments, a Shanghai government notice of 9 December 2025 states. Listing brings hospital access but at negotiated prices well below launch levels, a Douglas Insights estimate. Generics take the rest: GSK’s International region sales, which include most of its Asian business, fell 4% to GBP 2,028 million in the third quarter of 2026, its results announcement of 28 October 2026 shows. These restraints are already netted into the 3.20% course leg and 1.28% price leg above. How hospitals detect the infections these drugs treat is covered in our Hospital Acquired Infection Testing Kit Market report.

Which Asia Pacific countries spend most on infectious disease treatment: China, Japan or India?

China spends the most, USD 10.9 billion or 38.0% of 2025 Asia Pacific value, a Douglas Insights estimate. India grows fastest, 7.00% a year, from USD 3.75 billion to USD 7.37 billion by 2035.

We count value where the patient is treated. China leads because its public hospitals use more intravenous antibiotics per admission than most countries, and because chronic hepatitis B treatment is widespread; growth of 4.20% a year is held back by reimbursement and tender pricing. Japan, USD 5.47 billion, pays the region’s highest prices per course and buys most of its influenza and COVID-19 antivirals, but grows only 2.00% as respiratory antiviral sales fall and the national health insurance price list is revised down; Shionogi’s ensitrelvir won Japanese approval for preventing COVID-19 after exposure in March 2026, its pipeline update of 29 October 2026 shows.

India, USD 3.75 billion, grows fastest at 7.00% a year, because it carries a quarter of the world’s tuberculosis, resistance rates in its hospitals are among the highest anywhere, and new home-grown antibiotics such as Zaynich and Wockhardt’s Miqnaf (nafithromycin), approved and launched in India, add higher-priced courses, per the Wockhardt release of 2 November 2026. Southeast Asia, USD 3.46 billion, grows 6.20% on Indonesia’s and the Philippines’ tuberculosis programmes and on rising hospital capacity in Vietnam. South Korea, USD 1.73 billion, and Australia and New Zealand, USD 1.44 billion, grow 3.50% and 3.20%, led by hospital antifungals and new antibiotics. Regional values sum to USD 30.1 billion in 2026, 0.15% below the headline, and USD 44.6 billion in 2035, 0.44% below it; in the data table the row labelled Global holds the Asia Pacific total.

Which companies lead: Pfizer, Gilead Sciences or MSD?

Pfizer holds the largest share of Asia Pacific anti-infective value, about 6.0% of 2025, USD 1.73 billion, Douglas Insights estimates. With Gilead Sciences and MSD the top three hold only about 15.5%, because generic makers supply most courses.

The shares are Douglas Insights estimates because companies do not report Asia Pacific anti-infective sales in one place. Gilead’s HIV sales rose 18% to USD 6.2 billion worldwide in the third quarter of 2026, and the company extended its six royalty-free voluntary licences for twice-yearly lenacapavir to cover once-yearly lenacapavir for HIV prevention, if approved, in 120 high-incidence countries, its release of 29 October 2026 states. GSK’s HIV sales were GBP 2,116 million in the same quarter, up 9% at actual exchange rates, its results announcement of 28 October 2026 shows. Shionogi earned JPY 148.5 billion of HIV royalties from ViiV-sold medicines in the six months to September 2026, up 18.0%, and its China subsidiary JPY 2.7 billion, down 8.8%, its supplement shows; the royalties are earned worldwide and sit outside this market.

Indian makers matter more by volume than by value. Dr. Reddy’s agreed with Unitaid, the Clinton Health Access Initiative (CHAI) and Wits RHI to supply generic lenacapavir at USD 40 per person per year in 120 low- and middle-income countries from 2027, and the Gates Foundation reached a separate agreement with Hetero Labs, Unitaid’s release of 24 September 2025 states. Wockhardt is the first Indian company to take a home-discovered antibiotic through the FDA, which gives it a branded product in a market dominated by generics. Competition among multinationals turns on new hospital agents for resistant infections; among Indian and Chinese makers it turns on cost and tender wins.

What does a course of anti-infective treatment cost across the region?

An Asia Pacific anti-infective treatment course averaged about USD 16.2 at net prices in 2025, Douglas Insights estimates, from under a dollar for a generic antibiotic in India to thousands of dollars for a reserve antibiotic course in Japan.

The bands are Douglas Insights estimates of net prices after discounts, except the USD 40 lenacapavir figure, which Unitaid published in its release of 24 September 2025 together with a cap of USD 17 for the oral course. The average is low because about 19 in 20 courses are short generic antibiotic or antiviral courses, while hospital and reserve agents earn most of the value. Price per course rises 1.28% a year, to about USD 16.4 in 2026 and USD 18.4 in 2035, as reserve antibiotics and antifungals gain share; reimbursement negotiation in China and price revisions in Japan hold the rise down. The Global Fund expects initial generic lenacapavir supply in late 2026, with broader availability during 2027, its notice of 24 September 2026 states, which keeps HIV prevention cheap per patient in donor-funded countries.

Which rules shape the market: China’s reimbursement list, India’s CDSCO or Japan’s and Australia’s regulators?

Four rule sets shape Asia Pacific infectious disease treatment: China’s national reimbursement drug list, India’s CDSCO approvals and antibiotic supply rules, Japan’s approvals and price list, and Australia’s Therapeutic Goods Administration (TGA) approvals of new antibiotics.

China’s list decides which hospital drugs reach patients at scale. Its 2025 update added 114 medicines, 50 of them classed as Category 1 innovative drugs, with 88% of candidate drugs added against 76% a year earlier, the Shanghai government notice of 9 December 2025 states. We assume new anti-infectives that list in China lose most of their launch premium but gain hospital volume within two years, a Douglas Insights estimate.

India’s regulator is moving from controlling antibiotic supply to approving new ones. CDSCO’s Subject Expert Committee approved Zaynich’s clinical data on 10 March 2026, Wockhardt’s first-quarter FY27 release of 10 August 2026 states, and the same release reports the removal of a supply condition on Miqnaf by the Drugs Controller General of India; full manufacturing and marketing approval followed on 25 August 2026, the second-quarter release states. Japan approved ensitrelvir for post-exposure prevention of COVID-19 in March 2026 and Australia approved cefiderocol in September 2026, Shionogi’s supplement of 29 October 2026 shows. Donor rules matter too: the Global Fund told countries that national regulatory approval and registration of all generic lenacapavir sources is critical to supply, its notice of 24 September 2026 states.

What if resistance spreads faster or generic prices fall further: where does the market land in 2035?

The Asia Pacific infectious disease treatment market ends 2035 between USD 38.8 billion and USD 51.0 billion across our three cases, around a USD 44.8 billion base; South Asian access and reserve antibiotic uptake set the spread.

In the slower case donor funding for tuberculosis and HIV keeps shrinking, China’s reimbursement talks cut prices harder and Japan’s respiratory antiviral sales keep falling, taking 0.80 points off courses and 0.68 points off price. WHO already counts only USD 5.9 billion of tuberculosis funding available in 2024, just over a quarter of the USD 22 billion annual target for 2027, its release of 12 November 2025 states. In the faster case resistance spreads faster, more hospitals in India and Southeast Asia adopt reserve antibiotics such as Zaynich and cefiderocol, and diagnosis of tuberculosis and hepatitis B improves, adding 0.70 points to courses and 0.62 points to price. One extra point of yearly revenue growth adds about USD 4.01 billion to 2035 value; one point less removes about USD 3.72 billion.

Our 4.52% sits above the 3.32% in our worldwide Infectious Disease Treatment Market report and well above the 2.86% in our U.S. Infectious Disease Treatment Market report, because Asia Pacific adds treated patients faster and starts from a much lower price per course.

Douglas Exclusive: the Asia Pacific Resistance and Access Ledger

The Asia Pacific Resistance and Access Ledger is a Douglas Insights model built from 10 inputs in 7 company, UN and government documents dated September 2025 to November 2026. It tests whether closing gaps or fighting resistance adds more value.

The finding, a Douglas Insights estimate: closing the region’s two largest treatment gaps adds far less value than resistance does. Raising HIV treatment coverage from 72% to 95% of the 7.1 million people living with HIV in the UNAIDS July 2026 data adds about 1.63 million patients, worth about USD 122 million a year at a generic USD 75 per patient-year. Treating the 22% of tuberculosis patients missed in the six Asia Pacific countries named in the WHO release of 12 November 2025, about 1.37 million people, adds about USD 137 million at USD 100 a course. Together that is about USD 259 million, 0.90% of 2025 value. By contrast, reserve antibiotics rising from 12% to 18% of antibacterial value lift that tier from USD 1.52 billion in 2025 to about USD 3.48 billion in 2035, an extra USD 1.96 billion, about 7.5 times the gap-closing value.

The ledger changes how to read the market. Average HIV value per treated person in Asia Pacific is only about USD 789 a year, USD 4.03 billion across about 5.11 million patients, because generics dominate outside Japan, Australia and Korea. Companies that want value growth in the region should follow resistance into hospitals, where WHO’s 1 in 3 rate turns cheap first-line courses into expensive second-line ones; donors and generic makers, not branded companies, will close the access gaps.

How does the methodology turn 1.78 billion treatment courses into USD 28.8 billion?

Our methodology multiplies about 1.78 billion anti-infective treatment courses used in Asia Pacific in 2025 by an average USD 16.2 a course to reach USD 28.8 billion. Courses and prices come from class and country builds.

The model covers 7 countries and sub-regions, 6 drug classes, 2 care settings and 3 channels, and uses 126 data points, 27 sourced and 99 modelled. HIV and hepatitis patient-years are counted as courses. Yen figures are converted at JPY 150 and pound figures at USD 1.34, the Douglas Insights 2026 averages. Arithmetic: 1.78 billion x USD 16.19 = USD 28.8 billion; USD 28.8 billion x (1.0320 x 1.0128)^10 = USD 44.8 billion. Courses reach about 1.84 billion in 2026 and 2.44 billion in 2035; price reaches about USD 16.4 in 2026; 2026 value is USD 30.1 billion.

Two cross-checks agree. First, the Asia Pacific row of our worldwide Infectious Disease Treatment Market model is USD 28.8 billion in 2025, USD 30.1 billion in 2026 and USD 44.8 billion in 2035, and this report matches it in every year. Second, the tuberculosis and HIV populations in the WHO and UNAIDS releases linked above, about 6.23 million tuberculosis patients and 5.11 million people on HIV treatment, put antimycobacterial value at about USD 278 per tuberculosis patient and HIV value at about USD 789 per treated person, both in line with a generic-led market with branded pockets in Japan, Korea and Australia. AI tools help draft the text and automated checks test the arithmetic and links; the Douglas Insights research desk chooses the sources, builds the model and approves publication, as our editorial standards explain.

Sources

1. Wockhardt Wockhardt Q2 FY27 results press release (2026)
2. Wockhardt Wockhardt Q1 FY27 results press release (2026)
3. World Health Organization WHO warns of widespread resistance to common antibiotics worldwide (2025)
4. World Health Organization Global gains in tuberculosis response endangered by funding challenges (2025)
5. UNAIDS Global HIV & AIDS statistics fact sheet 2026 (2026)
6. Unitaid Landmark agreement with Dr. Reddy's to make lenacapavir affordable in LMICs (2025)
7. The Global Fund Global Fund prepares major expansion of lenacapavir generic supply (2026)
8. Shanghai Municipal People's Government China releases new insurance-covered medicine list (2025)
9. Shionogi Financial results for the 2nd quarter of FY2026, supplement (2026)
10. Gilead Sciences Gilead Sciences announces third quarter 2026 financial results (2026)
11. GSK GSK Q3 2026 results announcement (2026)

What counts in the market, and what is excluded?

The Asia Pacific infectious disease treatment market counts prescription anti-infective medicines used in Asia Pacific, valued at net manufacturer prices. Vaccines, monoclonal antibodies for prevention, diagnostics, disinfectants and over-the-counter products are excluded.

The by-class split covers the six drug classes above; the by-care-setting split covers hospital-treated and community infections; the by-channel split covers hospital pharmacies, retail pharmacies, and donor and public tenders; the by-region split covers China, Japan, India, Southeast Asia, South Korea, Australia and New Zealand, and the rest of Asia Pacific, including Pakistan, Bangladesh and the Pacific islands. Value is counted where the patient is treated, not where the drug is made, so Indian and Chinese exports to other regions are excluded. Laboratory tests that guide antibiotic choice are sized in our PCR and Real-Time PCR Molecular Diagnostics Market report.